Clinical trials
Human Papillomavirus Infection clinical trials
Below are recruiting human papillomavirus infection clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07833852Enrolling by invitation
Long-term protection study for bivalent HPV vaccine
This study follows up with people who received the bivalent HPV vaccine to see how long their protection lasts and whether any breakthrough infections occur. It involves extra blood tests or follow-up visits over several years.
Mianyang, SichuanAges 12–34 - NCT07706673Enrolling by invitationPhase 4
Long-term follow-up for HPV vaccine study participants
This study checks on people who got one or two doses of the HPV vaccine (Gardasil 9) during the earlier ESCUDDO study. It helps researchers see how well the vaccine protects over many years, which might lead to simpler vaccination schedules.
Liberia, Guanacaste ProvinceAges 18 years+ - NCT07601074RecruitingPhase 2
Testing DARE-HPV to Clear Persistent HPV Infection
This study tests whether DARE-HPV, a new treatment, can help your body clear a persistent human papillomavirus (HPV) infection that hasn't gone away on its own. HPV is a common virus; persistent infection with certain high-risk types can lead to cervical cancer, so clearing it early may prevent future problems.
Phoenix, ArizonaAges 22–50 - NCT07281430Recruiting
HPV self-test for cervical cancer screening
This study tests if a self-collected sample for HPV testing works as well as standard colposcopy to prevent cervical cancer. If you've recently had an abnormal cervical cancer screening and need a colposcopy, this trial may be an option for you.
Birmingham, AlabamaAges 25 years+ - NCT07209917Recruiting
Cervical cancer prevention for women with HIV and HPV
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
Bangalore, KarnatakaAges 25–50 - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT07186530Enrolling by invitation
HPV self-collection for cervical cancer screening
This trial tests a new way for women to screen for cervical cancer by collecting their own sample for HPV testing at home or in a clinic. It aims to make screening easier for those who are overdue and may be anxious about a pelvic exam.
Rochester, MinnesotaAges 30–63 - NCT05334706RecruitingPhase 4
Vaccine study to lower HPV spread in HPV-positive women
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
L'Hospitalet de Llobregat, CataloniaAges 18 years+ - NCT07275333Recruiting
HPV self-sampling for cervical screening in Ukraine
This trial tests if women can collect their own samples at home to check for HPV, a virus that can cause cervical cancer. It aims to make screening easier during the war in Ukraine.
ZaporizhzhyaAges 30–60 - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT05918510Recruiting
Blood and tumor study for virus markers in throat cancer
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
RomeAges 18 years+ - NCT07550010Recruiting
Digital Screening for Cervical Cancer in Cameroon
This study tests a new digital imaging method to help screen women for cervical cancer risk in Cameroon. It may help catch cervical problems earlier using easier-to-read pictures of the cervix.
YaoundéAges 25–50 - NCT07461818Recruiting
Quick treatment for cervical pre-cancer
This trial tests a new way to quickly diagnose and treat cervical pre-cancer using a point-of-care device. It may help women who are HPV-positive avoid a separate treatment visit.
San Salvador, San Salvador DepartmentAges 30–49 - NCT06862102Recruiting
Multiple HPV Infections and Cervical Lesion Risk
This study looks at how having multiple types of HPV virus affects the development of abnormal cervical cells (called CIN). It may help doctors understand why some people are more at risk and could lead to better prevention.
Pavia, PaviaAges 18 years+ - NCT06598475Recruiting
Improving HPV vaccination in Latino teens at health centers
This trial tests a program to help community health centers recommend and boost HPV vaccination rates among Latino adolescents aged 11-12. It aims to support health care providers and staff with education and resources.
Houston, TexasAges 11–17 - NCT05774561Recruiting
Using blood tests to monitor HPV-related cancer treatment
This study checks whether “liquid biopsies” (blood tests that look for cancer-related signals) can help monitor how HPV-related cancers respond to treatment. It may help doctors spot changes earlier during care.
OlomoucAges 18–99 - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT04226313Recruiting
Home self-swab tests for people not doing cervical screening
This study looks at whether a home self-sampling swab can help people who haven’t joined cervical cancer screening in the past few years. If you qualify, you’ll be asked to collect a swab yourself so it can be tested, aiming to make screening easier to access.
OlomoucAges 30–65 - NCT06995157Recruiting
HPV infections and vaccine attitudes in Slovenian women
This observational study looks at HPV infections and women's views about the HPV vaccine in Slovenia. It aims to understand the characteristics of HPV infections and attitudes toward vaccination after the vaccine became available.
Ljubljana, Municipality of DomžaleAges Up to 35 years - NCT07668271RecruitingPhase 4
HPV 9-valent vaccine lot consistency trial for women
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Zhangping, FujianAges 18–30 - NCT05985681RecruitingPhase 1
Vaccine to prevent HPV-related cancers
This trial tests a new vaccine called RG1-VLP that may help prevent cancers caused by HPV. It is for healthy women who have not had an HPV vaccine before and are willing to follow study procedures.
Madison, WisconsinAges 18–60 - NCT07281599Recruiting
Using a pad to screen for cervical precancer
This trial tests whether a special pad you wear during your period can detect signs of cervical precancer. If you are already scheduled for a colposcopy due to an abnormal Pap or HPV test, you might be able to participate.
New Haven, ConnecticutAges 25 years+ - NCT06129253Recruiting
GLOBE-HPV: Study of HPV in communities
This study is trying to find out how many people in different communities have HPV (human papillomavirus). It involves collecting samples and answering questions to help estimate the global burden of HPV.
DhakaAges 9–50 - NCT06997094RecruitingPhase 1
Decitabine plus standard therapy for HPV-negative head and neck cancer
This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.
Jacksonville, FloridaAges 18 years+
Hear when a new Human Papillomavirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human papillomavirus infection?
- Yes. Clin2 currently lists 40 recruiting human papillomavirus infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human papillomavirus infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human papillomavirus infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.